Strategic Leadership AM-Pharma recently appointed Juliane Bernholz as CEO, signaling a potential shift in strategic focus and fundraising capability. Engage to understand new leadership priorities, potential partnerships, and opportunities for strategic collaborations or licensing.

Clinical Focus The company targets adult hypophosphatasia with ilofotase alfa, an enzyme replacement therapy. Explore collaboration opportunities in rare disease trials, compassionate use programs, and potential co-development or manufacturing partnerships to accelerate clinical timelines.

Manufacturing Synergy AM-Pharma has established relationships in manufacturing (e.g., KBI Biopharma collaboration for recAP). There may be openings for contract development and manufacturing, supply chain optimization, or generic/adjacent enzyme production partnerships to scale operations.

Funding & Growth Revenue range indicates early-stage commercialization potential with room for strategic investors or grants. Approach with value propositions around market access strategies, payer engagement, and milestones tied to regulatory and clinical progress.

Market Access Past hires include VP of Value & Market Access, highlighting emphasis on reimbursement and market access readiness. Develop sales plays around health economics, payer perspectives, and evidence generation to support rapid payer acceptance post-approval.